0001104659-20-056881.txt : 20200505
0001104659-20-056881.hdr.sgml : 20200505
20200505161607
ACCESSION NUMBER: 0001104659-20-056881
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200412
FILED AS OF DATE: 20200505
DATE AS OF CHANGE: 20200505
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Deliargyris Efthymios
CENTRAL INDEX KEY: 0001751617
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 20849050
MAIL ADDRESS:
STREET 1: C/O PLX PHARMA,INC.8285 EL RIO STREET
STREET 2: SUITE 210
CITY: HOUSTON
STATE: TX
ZIP: 77054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
4
1
tm2018632-3_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-04-12
0
0001175151
Cytosorbents Corp
CTSO
0001751617
Deliargyris Efthymios
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION
NJ
08852
0
1
0
0
Chief Medical Officer
Common Stock
2020-04-12
4
A
0
140000
0
A
140000
D
Stock Option (right to buy)
6.59
2020-04-12
4
A
0
85500
0
A
2030-04-12
Common Stock
85500
85500
D
Dr. Deliargyris was appointed as Chief Medical Officer of CytoSorbents Corporation (the "Company"), effective May 1, 2020. This Form 4 is being filed to report certain transactions made in connection with that certain Employment Agreement, dated April 12, 2020, by and between Dr. Deliargyris and the Company (the "Employment Agreement").
Reflects the grant of (i) 120,000 restricted stock units, which shall fully vest as of and only upon a Change of Control (as defined in the Employment Agreement) and subject to the Reporting Person's continued employment as of the consummation of the Change of Control and (ii) 20,000 restricted stock units, which vest upon the earlier of (a) a Change of Control and (b) April 12, 2024, in each case, subject to the Reporting Person's continued employment as of the applicable vesting date. The restricted stock units will automatically settle into shares of the Company's common stock, $0.001 par value per share (the "Common Stock") upon vesting.
Reflects the grant of a stock option to purchase 85,500 shares of the Company's Common Stock. The shares underlying the stock option will vest over four years from the date of the grant, with (i) 30,000 shares underlying such option vesting immediately on the date of grant and becoming exercisable on October 12, 2020, and (ii) the remaining 55,000 shares underlying such option vesting and becoming exercisable in three approximately equal installments on the first, second and third anniversary of the date of grant, in each case, subject to the Reporting Person's employment on the applicable vesting date.
/s/ Kathleen P. Bloch, attorney-in-fact for Efthymios Deliargyris
2020-05-05